Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults – a retrospective, single institute experience - Takeaways - MDSpire

Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults – a retrospective, single institute experience

  • By

  • Fabian J. K. Allmendinger

  • Maximilian Deng

  • Sebastian Regnery

  • Lars Wessel

  • Katharina Kozyra

  • Felix Englert

  • Ricarda Wickert

  • Jannik Walter

  • Lucas Mose

  • Thomas Tessonnier

  • Sandro M. Krieg

  • Jürgen Debus

  • Laila König

  • Tanja Adena-Eichkorn

  • June 12, 2026

  • 0 min

Share

  • 1

    Pituitary adenomas (PAs) can cause significant morbidity due to endocrine dysfunction and local mass effects.

  • 2

    Subtotal resection of PAs is common, with regrowth occurring in up to 60% of patients, necessitating additional treatment strategies.

  • 3

    Proton beam radiotherapy (PRT) offers advantages in sparing normal tissue compared to conventional radiotherapy for complex residual PAs.

  • 4

    This study reports on 22 adult patients receiving adjuvant PRT for residual PAs, highlighting the need for multidisciplinary decision-making.

  • 5

    Data collection included patient characteristics, tumor imaging, and follow-up reports to assess the long-term effects of PRT.

Original Source(s)

Long-term outcomes of adjuvant proton radiotherapy (PRT) for residual pituitary adenoma (PA) in adults – a retrospective, single institute experience

  • by Fabian J. K. Allmendinger, Maximilian Deng, Sebastian Regnery, Lars Wessel, Katharina Kozyra, Felix Englert, Ricarda Wickert, Jannik Walter, Lucas Mose, Thomas Tessonnier, Sandro M. Krieg, Jürgen Debus, Laila König, Tanja Adena-Eichkorn

  • June 12, 2026

Related Content

Artificial intelligence for biomarker prediction in gastric cancer: from histopathology to multimodal integration

2026 AACR Renal Cell Carcinoma Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the renal cell carcinoma clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min
PTHrP-associated hypercalcemia in gynecologic malignancies: a scoping review